PDIA3P1 and glioblastoma: Consistent with previous results, survival analysis demonstrated that both LGG and GBM patients with higher PDIA3P1 levels had shorter overall survival times than those with lower levels, according to the TCGA and CGGA databases (Fig. 1i–l).